Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 23Mitoxantrone 9Etoposide 8Idarubicin 5Filgrastim 5tipifarnib 4fludarabine phosphate 4Daunorubicin 4Cyclophosphamide 4Topotecan 3Sorafenib 3Clofarabine 3Bortezomib 3Azacitidine 3tanespimycin 2alvocidib 2Peripheral Blood Stem Cell Transplantation 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Everolimus 2Cladribine 2Carboplatin 2Busulfan 2Arsenic Trioxide 2venetoclax 1veliparib 1trebananib 1sargramostim 1romiplostim 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Monocytic, Acute × XK 469 × Clear all
NCT00095797 2013-02-08

XK469R in Treating Patients With Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡